1. Home
  2. Research
  3. Research Groups
  4. Surgical research in urology and renal trasplantation

Surgical research in urology and renal trasplantation

Search for publications

Only original articles, editorials, guidelines.

  • Ciccarese C, Büttner T, Cerbone L, Zampiva I, Monteiro FSM, Basso U, Pichler M, Vitale MG, Fiala O, Roviello G, Kopp RM, Carrozza F, Pichler R, Grillone F, Calabuig EP, Zeppellini A, Küronya Z, Galli L, Facchini G, Sunela K, Mosca A, Molina-Cerrillo J, Spinelli GP, Ansari J, Scala A, Mollica V, Grande E, Buti S, Kanesvaran R, Zakopoulou R, Bamias A, Rizzo M, Massari F, Iacovelli R, Santoni M.

    Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study).

    INTERNATIONAL JOURNAL OF CANCER . 155(11): 2036-2046.

    [doi:10.1002/ijc.35141]

  • Medina, Alberto Artiles, Ojeda, Cesar Minguez, Henriquez, Jose Daniel Subiela, Garcia, Alfonso Muriel, Gonzalez, alvaro Sanchez, Alcaraz, Marina Mata, Burgos, Jennifer Brasero, Borau, Pablo Gajate, Dos Santos, Victoria Gomez, Cidre, Miguel Angel Jimenez, Revilla, Francisco Javier Burgos.

    Nomograms to Appraise The Risk of Chronic Kidney Disease After Radical Cystectomy: Shifting The Focus to Prevention

    CLINICAL GENITOURINARY CANCER . 22(6): 102205-102205.

    [doi:10.1016/j.clgc.2024.102205]

  • Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ.

    Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.

    LANCET . 404(10460): 1309-1320.

    [doi:10.1016/S0140-6736(24)01758-6]

  • Ruiz Torres I, Serrano AB, Juez LD, Ballestero Pérez A, Ocaña Jiménez J, Die Trill J, Fernandez Cebrian JM, García Pérez JC.

    Cost-benefit analysis and short-term outcomes after implementing an ERAS protocol for colorectal surgery: a propensity score-matched analysis.

    TECHNIQUES IN COLOPROCTOLOGY . 28(1): 130-130.

    [doi:10.1007/s10151-024-02997-1]

  • Caliskan E, Misfeld M, Sandner S, Böning A, Aramendi J, Salzberg SP, Choi YH, Perrault LP, Tekin I, Cuerpo GP, Lopez-Menendez J, Weltert LP, Böhm J, Krane M, González-Santos JM, Tellez JC, Holubec T, Ferrari E, Doros G, Emmert MY.

    Transatlantic analysis of patient profiles and mid-term survival after isolated coronary artery bypass grafting: a head-to-head comparison between the European DuraGraft Registry and the US STS Registry.

    Frontiers in Cardiovascular Medicine . 11: 1366460-1366460.

    [doi:10.3389/fcvm.2024.1366460]

  • Rizzo A, Monteiro FSM, Ürün Y, Massari F, Park SH, Bourlon MT, Poprach A, Rizzo M, Takeshita H, Giannatempo P, Soares A, Roviello G, Molina-Cerrillo J, Carrozza F, Abahssain H, Messina C, Kopp RM, Pichler R, Formisano L, Tural D, Atzori F, Calabrò F, Kanesvaran R, Buti S, Santoni M.

    Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.

    TARGETED ONCOLOGY . 19(5): 747-755.

    [doi:10.1007/s11523-024-01089-2]

  • Ruz-Caracuel I, Caniego-Casas T, Alonso-Gordoa T, Carretero-Barrio I, Ariño-Palao C, Santón A, Rosas M, Pian H, Molina-Cerrillo J, Luengo P, Palacios J.

    Transcriptomic Differences in Medullary Thyroid Carcinoma According to Grade.

    ENDOCR PATHOL . 35(3): 207-218.

    [doi:10.1007/s12022-024-09817-0]

  • Laszkiewicz J, Krajewski W, Sójka A, Nowak L, Chorbinska J, Subiela JD, Tomczak W, Del Giudice F, Malkiewicz B, Szydelko T.

    Blood-, Tissue- and Urine-Based Prognostic Biomarkers of Upper Tract Urothelial Carcinoma.

    DIAGNOSTICS . 14(17): .

    [doi:10.3390/diagnostics14171927]

  • Albarrán V, Guerrero P, de Quevedo CG, González C, Chamorro J, Rosero DI, Moreno J, Calvo JC, de Aguado PP, Alía V, Sotoca P, Barrill AM, Román MS, Álvarez-Ballesteros P, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Garrido P, Gajate P.

    Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 73(10): 186-186.

    [doi:10.1007/s00262-024-03772-9]

  • Gómez-Gómez E, Martínez-Salamanca JI, Bianco F, Miles BJ, Burgos J, Quintas JJ, Cano-Castiñeira R, Gómez-Ferrer Á, Rodríguez-Antolín A, Chéchile G, Fernández L, Martín A, Hidalgo P, Parramón M.

    ProsTAV, a clinically useful test in prostate cancer: an extension study.

    WORLD JOURNAL OF UROLOGY . 42(1): 395-395.

    [doi:10.1007/s00345-024-05098-8]

  • Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, Grande E, De Giorgi U, Molina-Cerrillo J, Seront E, Calabrò F, Myint ZW, Facchini G, Kopp RM, Berardi R, Kucharz J, Vitale MG, Pinto A, Formisano L, Büttner T, Messina C, Monteiro FSM, Battelli N, Kanesvaran R, Büchler T, Kopecký J, Santini D, Giudice GC, Porta C, Santoni M.

    Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).

    TARGETED ONCOLOGY . 19(4): 587-599.

    [doi:10.1007/s11523-024-01065-w]

  • Scilipoti P, Slusarczyk A, de Angelis M, Soria F, Pradere B, Krajewski W, D'Andrea D, Mari A, Giudice FD, Pichler R, Subiela JD, Afferi L, Albisinni S, Mertens L, Laukhtina E, Mori K, Radziszewski P, Shariat SF, Necchi A, Xylinas E, Gontero P, Rouprêt M, Montorsi F, Briganti A, Moschini M.

    The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.

    European Urology Oncology . : .

    [doi:10.1016/j.euo.2024.06.005]

  • Sáenz-Medina J, Gómez Dos Santos V, Rodríguez-Monsalve M, Muriel-García A, Durán-Poveda M, Gómez Del Val A, Burgos Revilla J, Prieto D.

    Cardiovascular and Cerebrovascular Morbidity in Patients with Urolithiasis: An Epidemiological Approach Based on Hospitalization Burden Data from 1997 to 2021.

    Journal Of Clinical Medicine . 13(12): .

    [doi:10.3390/jcm13123564]

  • Incorvaia L, Monteiro FSM, Massari F, Park SH, Roviello G, Fiala O, Myint ZW, Kucharz J, Molina-Cerrillo J, Santini D, Buttner T, Poprach A, Kopecky J, Zeppellini A, Pichler M, Buchler T, Pichler R, Facchini G, Fay AP, Soares A, Manneh R, Iezzi L, Kuronya Z, Russo A, Bourlon MT, Bhuva D, Ansari J, Kanesvaran R, Grande E, Buti S, Santoni M.

    Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 73(8): 142-142.

    [doi:10.1007/s00262-024-03719-0]

  • Rizzo A, Buti S, Giannatempo P, Salah S, Molina-Cerrillo J, Massari F, Kopp RM, Fiala O, Galli L, Myint ZW, Tural D, Soares A, Pichler R, Mennitto A, Abahssain H, Calabrò F, Monteiro FSM, Albano A, Mollica V, Giudice GC, Takeshita H, Santoni M.

    Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.

    CLINICAL & EXPERIMENTAL METASTASIS . : .

    [doi:10.1007/s10585-024-10296-0]

  • López Valcárcel M, Barrado Los Arcos M, Ferri Molina M, Cienfuegos Belmonte I, Duque Santana V, Gajate Borau P, Fernández Ibiza J, Álvarez Maestro M, Sargos P, López Campos F, Couñago F.

    Is trimodal therapy the current standard for muscle-invasive bladder cancer?

    Actas Urologicas Espanolas . 48(5): 345-355.

    [doi:10.1016/j.acuroe.2024.04.001]

  • Núñez-Gil IJ, Rodríguez-Caulo EA, García-Cosío MD, Piñón M, Díez-Del Hoyo F, Eixerés A, Carrasco-Chinchilla F, López-Menéndez J, Pérez-Villacastín J, Rodríguez-Roda J.

    Cardiovascular surgery and cardiology, current status of two sister specialties in Spain: the CARDIOXCARDIO study.

    Revista espanola de cardiologia (English ed.) . : .

    [doi:10.1016/j.rec.2024.05.004]

  • Caño Velasco J, Artero Fullana S, Polanco Pujol L, Lafuente Puentedura A, Subiela JD, Aragón Chamizo J, Moralejo Gárate M, Hernández Fernández C.

    Use of Bladder Epicheck® in the follow-up of high-risk non-muscle-invasive Bladder cancer: A systematic literature review.

    Actas Urologicas Espanolas . : .

    [doi:10.1016/j.acuroe.2024.05.004]